Interim analysis of a non-interventional study evaluating the quality of life in second-line treatment of metastatic renal cell carcinoma with everolimus (EVERPRO).

Bergmann, L., Goebell, P., Kloß, S., Schirrmacher-Memel, S., Warnack, W., Kube, U., Scheffler, M., Doehn, C., Marschner, N., Rosé, C., Herrmann, E., 2014.

Oncol Res Treat 37 (suppl.5)(P282), 89. doi:10.1159/000368945

Studie: EVERPRO; Indikation: Nierenzellkarzinom; Jahr: 2014; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com